Recent Analysts’ Ratings Changes for Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics (NASDAQ: FULC) recently received a number of ratings updates from brokerages and research firms:

• 11/1/2025 – Fulcrum Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 10/30/2025 – Fulcrum Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $16.00 price target on the stock, up previously from $12.50.
• 10/30/2025 – Fulcrum Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $7.00. They now have a “sector perform” rating on the stock.
• 10/21/2025 – Fulcrum Therapeutics was given a new $20.00 price target on by analysts at Leerink Partners. They now have an “outperform” rating on the stock.
• 10/20/2025 – Fulcrum Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
• 10/8/2025 – Fulcrum Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Fulcrum Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/26/2025 – Fulcrum Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.